β2肾上腺素受体结构研究进展
Current Progress of Structural Studies on β2 Adrenergic Receptor

作者: 唐令利 , 张 鹏 , 王先龙 :电子科技大学生命科学与技术学院,神经信息教育部重点实验室,四川 成都;

关键词: β2肾上腺素受体G蛋白偶联受体晶体结构激动剂反向激动剂拮抗剂β2 Adrenergic Receptor G Protein-Coupled Receptor Crystal Structure Agonist Inverse Agonist Antagonist

摘要:
β2肾上腺素受体(β2 adrenergic receptor, β2AR)是生命体中一类重要的G蛋白偶联受体。作为一种膜蛋白,由于结晶困难过去很难获得其晶体三维结构。近几年来,得益于蛋白质结晶技术和自由电子X射线晶体结构测定技术的进展,各种状态下的β2AR晶体结构获得解析。β2AR结构的发现丰富了人们对生命现象的解释,对于当今新药物设计具有重大意义。本文主要综述了β2肾上腺素受体晶体结构的发现历程、结构特征与不同类型配体(激动剂、反向激动剂和拮抗剂)的相互作用机制以及其在临床医学上的应用研究,并指出这一研究领域的未来发展方向。

Abstract: Beta-2 adrenergic receptor is an important member among G protein-coupled receptors superfa-mily. As a membrane protein, it is difficult to crystalize and its three-dimensional structure is not known until recent years. Thanks to the development of the crystal engineering techniques and the breakthroughs in the free electron X-ray laser crystallography, many crystal structures of β2 adrenergic receptor at different states become available now. The discovery of the crystal structure β2 adrenergic receptor has enriched our understanding on many life phenomena and its impact to the structure-based drug design cannot be overestimated. We review the discovery history of β2 adrenergic receptor crystal structures, the structural characteristics of the receptor, the in-teractions between the receptor and different subtypes of the ligands (agonist, inverse agonist and antagonist) and clinical applications.

文章引用: 唐令利 , 张 鹏 , 王先龙 (2015) β2肾上腺素受体结构研究进展。 药物化学, 3, 1-10. doi: 10.12677/HJMCe.2015.31001

参考文献

[1] Parnot, C. and Kobilka, B.K. (2004) Toward understanding GPCR dimer. Nature Structural and Molecular Biology, 11, 691-692.

[2] Buchen, L. (2011) Cell signalling: It’s all about the structure. Nature News, 476, 387-390.

[3] Pierce, K.L., Premont, R.T. and Lefkowitz, R.J. (2002) Seven-transmembrane receptors. Nature Reviews Molecular Cell Biology, 3, 639-650.

[4] Palczewski, K., Kumasaka, T., Hori, T., et al. (2000) Crystal structure of rhodopsin: A G pro-tein-coupled receptor. Science, 289, 739-745.

[5] Williams, R. (2013) Brian Kobilka: Chipping away at the β2-adrenergic receptor. Circulation Research, 112, 1538- 1541.

[6] Rasmussen, S.G., Choi, H.J., Fung, J.J., et al. (2011) Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature, 469, 175-180.

[7] Lefkowitz, R.J., Roth, J., Price, W., et al. (1970) ACTH receptors in the adrenal: Specific binding of ACTH 125I and its relation to adenylcyclase. Proceedings of the National Academy of Sciences, 65, 745-752.

[8] Kobilka, B.K., Dixon, R.A.F., Frielle, T., et al. (1987) cDNA for the human β2-adrenergic receptor: A protein with multiple membrane-spanning do-mains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proceedings of the National Academy of Sciences, 84, 46-50.

[9] Rasmussen, S.G., Choi, H.J., Rosenbaum, D.M., et al. (2007) Crystal structure of the human β2 adrenergic G-protein- coupled receptor. Nature, 450, 383-387.

[10] Kobilka, B.K. and Deupi, X. (2007) Conformational complexity of G-protein-coupled receptors. Trends in Pharmacological Sciences, 28, 397-406.

[11] Day, P.W., Rasmussen, S.G., Parnot, C., et al. (2007) A monoclonal antibody for G protein-coupled receptor crystallography. Nature Methods, 4, 927-929.

[12] Granier, S., Kim, S., Shafer, A.M., et al. (2007) Structure and conformational changes in the C-terminal domain of the β2-adrenoceptor insights from fluorescence resonance energy transfer. Journal of Biological Chemistry, 282, 13895- 13905.

[13] Rosenbaum, D.M., Cherezov, V., Hanson, M.A., et al. (2007) GPCR engineering yields high-resolution structural insights into β2-adrenergic receptor function. Science, 318, 1266-1273.

[14] Cherezov, V., Rosenbaum, D.M., Hanson, M.A., et al. (2007) High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science, 318, 1258-1265.

[15] Dror, R.O., Pan, A.C., Arlow, D.H., et al. (2011) Pathway and mechanism of drug binding to G-protein-coupled receptors. Proceedings of the National Academy of Sciences, 108, 13118-13123.

[16] Graaf, C.D. and Rognan, D. (2008) Selective structure-based virtual screening for full and partial agonists of the β2 adrenergic receptor. Journal of Medicinal Chemistry, 51, 4978-8495.

[17] Bokoch, M.P., Zou, Y.Z., Rasmussen, S.G., et al. (2010) Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature, 463, 108-112.

[18] Rasmussen, S.G., DeVree, B.T., Zou, Y., et al. (2011) Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature, 477, 549-555.

[19] Goldstein, J.L. and Brown, M.S. (2012) A golden era of Nobel laureates. Science, 338, 1033-1034.

[20] Clark, R.B. (2013) Profile of Brian K. Kobilka and Robert J. Lefkowitz, Nobel laureates in Chemistry. Proceedings of the National Academy of Sciences, 110, 5274-5275.

[21] Wei, L., Wacker, D., Gati, C., et al. (2013) Serial femtosecond crystallography of G protein-coupled receptors. Science, 342, 1521-1524.

[22] Hanson, M.A., Cherezov, V., Griffith, M.T., et al. (2008) A specific cholesterol binding site is established by the 2.8 Å structure of the human beta2-adrenergic receptor. Structure, 16, 897-905.

[23] Wacker, D., Fenalti, G., Brown, M.A., et al. (2010) Conserved binding mode of human β2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. Journal of the American Chemical Society, 132, 11443- 11445.

[24] Rosenbaum, D.M., Zhang, C., Lyons, J.A., et al. (2011) Structure and function of an irreversible agonist β2 adrenoceptor complex. Nature, 469, 236-240.

[25] Hover, D., Clarke, D.E., Fozard, J.R., et al. (1994) International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacological Reviews, 46, 157-203.

[26] Zou, Y.Z., Weis, W.I. and Kobilka, B.K. (2012) N-terminal T4 lysozyme fusion facilitates crystallization of a G protein coupled receptor. PloS ONE, 7, e46039.

[27] Ring, A.M., Manqlik, A., Kruse, A.C., et al. (2013) Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody. Nature, 502, 575-579.

[28] Weichert, D., Kruse, A.C., Manglik, A., et al. (2014) Covalent agonists for studying G protein-coupled receptor activation. Proceedings of the National Academy of Sciences, 111, 10744-10748.

[29] Lebon, G., Warne, T. and Tate, C.G. (2012) Agonist-bound structures of G protein-coupled receptors. Current Opinion in Structural Biology, 22, 482-490.

[30] Tate, C.G. (2012) A crystal clear solution for determining G-protein-coupled receptor structures. Trends in Biochemical Sciences, 37, 343-352.

[31] Milliqan, G. and Bond, R.A. (1997) Inverse agonism and the regulation of receptor number. Trends in Pharmacological Sciences, 18, 468-474.

[32] Sladek, F.M. (2011) What are nuclear receptor ligands? Molecular and Cellular Endocrinology, 334, 3-13.

[33] Lands, A.M., Arnold, A., McAuliff, J.P., Ludeuna, F.P. and Brown, T.G. (1967) This week’s citation classic: Differentiation of receptor systems activated by sympathomimetic amines. Nature, 214, 597-598.

[34] Nagatomo, T., Ohnuki, T., Ishiguro, M., Ahmed, M. and Nakamura, T. (2001) β-adrenoceptors: Three-dimensional structures and binding sites for ligands. The Japanese Journal of Pharmacology, 87, 7-13.

[35] Ghanouni, P., Gryczynski, Z., Steenhuis, J.J., et al. (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the β2 adrenergic receptor. Journal of Biological Chemistry, 276, 24433- 24436.

[36] Ghanouni, P., Steenhuis, J.J., Farrens, D.L. and Kobilka, B.K. (2001) Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor. Proceedings of the National Academy of Sciences, 98, 5997- 6002.

[37] Granier, S. and Kobilka, K.B. (2012) A new era of GPCR structural and chemical biology. Nature Chemical Biology, 8, 670-673.

[38] Feng, Z.W., Hou, T.J. and Li, Y.Y. (2012) Studies on the interactions between β2 adrenergic receptor and Gs protein by molecular dynamics simulations. Journal of Chemical Information and Modeling, 52, 1005-1014.

[39] Ranganathan, R. (2007) Signaling across the cell membrane. Science, 318, 1253-1254.

[40] Zocher, M., Zhang, C. and Rasmussen, S.G. (2012) Cholesterol increases kinetic, energetic, and mechanical stability of the human β2-adrenergic receptor. Proceedings of the National Academy of Sciences, 109, E3463-E3472.

[41] Costanzi, S. (2008) On the applicability of GPCR homology models to computer-aided drug discovery: A comparison between in silico and crystal structures of the β2-adrenergic receptor. Journal of Medicinal Chemistry, 51, 2907-2914.

[42] Rosenbaum, D.M., Rasmussen, S.G. and Kobilka, B.K. (2009) The structure and function of G-protein-coupled receptors. Nature, 459, 356-363.

[43] Bhattacharya, S. and Vaidehi, N. (2010) Computational mapping of the conformational transitions in agonist selective pathways of a G-protein coupled receptor. Journal of the American Chemical Society, 132, 5205-5214.

[44] Compiani, M. and Capriotti, E. (2013) Computational and theoretical methods for protein folding. Biochemistry, 52, 8601-8624.

[45] Sprang, S.R. (2011) Cell signalling: Binding the receptor at both ends. Nature, 469, 172-173.

[46] Roth, C.B., Hanson, M.A. and Stevens, R.C. (2008) Stabilization of the human β2-adrenergic receptor TM4-TM3-TM5 helix interface by mutagenesis of Glu1223.41, a critical residue in GPCR structure. Journal of Molecular Biology, 376, 1305-1319.

[47] Kaszuba, K., Róg, T., Bryl, K., et al. (2010) Molecular dynamics simulations reveal fundamental role of water as factor determining affinity of binding of β-blocker nebivolol to β2-adrenergic receptor. The Journal of Physical Chemistry B, 114, 8374-8386.

[48] Levit, A., Beuming, T., Krilov, G., et al. (2014) Predicting GPCR promiscuity using binding site features. Journal of Chemical Information and Modeling, 54, 184-194.

[49] Jacobson, K.A. and Costanzi, S. (2012) New insights for drug design from the X-ray crystallographic structural of G-protein-coupled receptors. Molecular Pharmacology, 2, 361-371.

[50] Taylor, M.R.G. (2006) Pharmacogenetics of the human beta-adrenergic receptors. The Pharmacogenomics Journal, 7, 29-37.

[51] Procoiou, P.A., Barrett, V.J., Bevan, N.J., et al. (2009) Synthesis and structure-activity relationships of long-acting β2 adrenergic receptor agonists incorporating arylsulfonamide groups. Journal of Medicinal Chemistry, 52, 2280-2288.

[52] Agache, I., Akdis, C., Jutel, M. and Virchow, J.C. (2012) Untangling asthma phenotypes and endotypes. Allergy, 67, 835-846.

[53] Bond, R.A. and Iizerman, A.P. (2006) Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends in Pharmacological Sciences, 27, 92-96.

[54] Parra, S. and Bond, R.A. (2007) Inverse agonism: From curiosity to accepted dogma, but is it clinically relevant? Current Opinion in Pharmacology, 7, 146-150.

[55] Nelson, C.P. and Challiss, R.A. (2007) “Phenotypic” pharmacology: The influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. Biochemical Pharmacology, 73, 737-751.

[56] Litonjua, A.A., Gong, L., Duan, Q.L., et al. (2010) Very important pharmacogene summary ADRB2. Pharmacogenetics and Genomics, 20, 64-69.

[57] Loza, M.J. and Penn, R.B. (2010) Regulation of T cells in airway disease by beta-agonist. Frontiers in Bioscience (Scholar Edition), 2, 969-979.

[58] Kern, C., Meyer, T., Droux, S., et al. (2009) Synthesis and pharmacological characterization of β2-adrenergic agonist enantiomers: Zilpaterol. Journal of Medicinal Chemistry, 52, 1773-1777.

[59] Larocca, N.E., Moreno, D., Garmendia, J.V., et al. (2011) Role of β2 agonists in respiratory medicine with particular attention to novel patents and effects on endocrine system and immune response. Recent Patents on Endocrine, Metabolic and Immune Drug Discovery, 5, 230-236.

[60] Jesudason, C.D., Baker, J.E., Bryant, R.D., et al. (2011) Combination of a beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity. ACS Medicinal Chemistry Letters, 2, 583-586.

[61] Pullar, C.E., Provost, G.S.L., Ó Leary, A.P., et al. (2012) β2AR antagonists and β2AR gene deletion both promote skin wound repair processes. Journal of Investigative Dermatology, 132, 2076-2084.

[62] Mckinnell, R.M., Klein, U., Linsell, M.S., et al. (2014) Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD. Bioorganic Medicinal Chemistry Letters, 24, 2871-2876.

[63] Manglik, A., Kruse, A.C., Kobilka, T.S., et al. (2012) Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature, 485, 321-326.

[64] Granier, S., Manglik, A., Kruse, A.C., et al. (2012) Structure of the δ-opioid receptor bound to naltrindole. Nature, 485, 400-404.

[65] Tautermann, C.S. and Pautsch, A. (2011) The implication of the first agonist bound activated GPCR X-ray structure on GPCR in silico modeling. ACS Medicinal Chemistry Letters, 2, 414-418.

[66] Bake, M. (2010) Making membrane proteins for structures: A trillion tiny tweaks. Nature Methods, 7, 429-434.

[67] Aristotelous, T., Ahn, S., Shukla, A.K., et al. (2013) Discovery of β2 adrenergic receptor ligands using biosensor fragment screening of tagged wild-type receptor. ACS Medicinal Chemistry Letters, 4, 1005-1100.

[68] Wang, P.L., Wang, Z. and Su, X.O. (2015) A sensitive and quantitative fluorescent multi-component immuno-chro- matographic sensor for β-agonist residues. Biosensors and Bioelectronics, 64, 511-516.

分享
Top